BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...
In recent health developments, the FDA approved a new drug by BridgeBio for a deadly heart condition. Additionally, Merck's ...
Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...
Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.
Kostas Biliouris, an analyst from BMO Capital, maintained the Hold rating on BridgeBio Pharma (BBIO – Research Report). The associated price ...
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
(In Nov. 22 story, corrects list price of Pfizer's drug to about $268,000 from $225,000 in paragraph 3) (Reuters) -The U.S.
European shares were higher today. The eurozone's STOXX 600 gained 0.16%, Germany's DAX gained 0.49% and France's CAC 40 rose ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback